In BRAF V600E-mutant HGG, dual BRAF and MEK inhibition affects glioma plasticity, promoting an immunomodulatory phenotype with elevated PD-L1 expression and improving the synergy with ICIs [167]. The gene discussed is BRAF; the disease is central nervous system cancer.